Loading…
Loading…
Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ: TWST) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,970 shares of the company's stock, valued at approximately $2,157,000. Twist Bioscience comprises
Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ: TWST) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 90,053 shares of the company's stock, valued at approximately $9,265,000. Deutsche Bank AG owned about 0.14% of Twist
Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist.
Twist Bioscience Corp (NASDAQ:TWST) shares surged Wednesday after Anthropic named the company an independent evaluator in a new AI-driven protein design campaign.
Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch goes well beyond chatbots. According to the Wall Street Journal, "Anthropic is targeting a public debut in September or early October, people familiar with its plans said." In those same meetings, the company told some investors that it... The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech)
On August 07, 2026, Twist Bioscience Corp (TWST) shares rose by 6.0%, bringing the current price to $115.67. The stock has experienced significant fluctuations,
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s share price shot up 10.3% during mid-day trading on Wednesday after Piper Sandler raised their price target on the stock from $85.00 to $115.00. Piper Sandler currently has an overweight rating on the stock. Twist Bioscience traded as high as $111.88 and last traded at $109.72. 593,619
Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve.